Go to http://www.manageyourtreatment.org for more information.
Cancer has touched the lives of all of us. Each year, it takes the lives of more than half a million Americans and seven million people worldwide.
Cynthia Nixon and Edie Falco will appear in this PSA to encourage cancer patients to win back some control in their lives by managing their treatment. In their role as the campaign ambassadors, Falco and Nixon appear to encourage people to better understand their options and provide support for managing their care.
PTSD treatment 1 week on former Birmingham soldier Craig Burgess talks about the changes in his PTSD post traumatic stress disorder and how all the nightmares and flashbacks have stopped after just one session with Birmingham NLP hypnotherapist Debbie Williams. Get a free hypnosis recording Stop worrying and create a wonderful life form here http://www.debbiewilliamsassociates.co.uk/home.htm
www.spineandjoint.asia - Spinecor™ bracing system uses a soft cotton brace that allows movement and correction of the spinal curvature for effective treatment of scoliosis.
Twelve-year-old Ugandan soccer star and malaria survivor Charles Ssali, together with Major League Soccer Commissioner Don Garber, is making a stop in New York today to formally launch the United Against Malaria campaign in the United States. Starting with a breakfast event in Times Square, Ssali will be welcomed to the United Nations by avid soccer fan, Deputy Secretary-General Dr. Asha-Rose Migiro.This initiative is a partnership that aims to harness the popularity of soccer and the excitement leading up to the 2010 FIFA World Cup South AfricaTM as a way to raise global awareness and build worldwide commitment to ending malaria, as well as increase the use of prevention tools and malaria treatment in Africa.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/thegatesfoundation/41028/
After a successful pilot program in October 2009, Cancer Treatment Centers of America (CTCA) is introducing an innovative approach to cancer treatment this July at each of its four hospitals in suburban Chicago, Philadelphia, Tulsa and suburban Phoenix. Called “Patient Empowered CareSM,” this advancement in the patient treatment delivery process offers patients an average of between two and three hours with a dedicated team of specialized oncology physicians and clinicians.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancercenter/44523/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
Close-Up TV News recognizes the Orthopaedic & Spine Institute for its remarkable commitment to quality care, providing relief to thousands of patients.
Spine surgery has advanced significantly over the past decade, allowing for more reliable outcomes, less surgical morbidity and quicker recovery. Dr Steven Cyr of the Orthopaedic & Spine Institute in San Antonio (http://www.saspine.com) offers some of the country’s most advanced training, compassionate care and individualized treatment options to help eliminate back and neck pain and improve his patients’ quality of life.
To view MultiMedia News Release, go to http://multivu.prnewswire.com/mnr/closeuptvnews/46410/
A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or ‘bird flu,’ even when given late in the course of illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/outcome/46648/
Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer.
With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
Two of the most advanced tools for precise, radiotherapy-based treatment are now under one roof in Seattle. Swedish Medical Center this month became the first facility in the Pacific Northwest – and one of only a handful in North America – to open a unit that incorporates both CyberKnife and Gamma Knife technologies. The 3,950-square-foot Swedish Radiosurgery Center, formerly known as the Seattle CyberKnife Center, is located on the
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
